Drug Trial Radar · NCT07070232
A Clinical Study to Test if an Investigational Treatment Called BNT326 is Safe and Potentially Beneficial When Used Alone or in Combination With Other Investigational Treatments Such as BNT327, for People With Advanced Malignant Tumors
Last checked: Nov 19, 2026Latest source record: Nov 18, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
1,438
Planned (sponsor's estimate)
Start
Aug 12, 2025
Primary completion
Mar 2028
Study completion Mar 2030
Sponsor
- Lead sponsor
- BioNTech SEIndustry
- Sponsor type
- Industry
- Collaborators
- BioNTech (Shanghai) Pharmaceuticals Co., Ltd.
- First posted
- Jul 17, 2025
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study will evaluate the safety, efficacy, optimal dose, and pharmacokinetics (PK) of BNT326 as monotherapy (Part 1) and as combination treatment with immunotherapeutic agents (Part 2) in participants with histologically or cytologically confirmed solid tumors that are advanced (i.e., either metastatic or recurrent tumors with no further definitive treatment possible) and/or have relapsed/progressed after prior therapy.
Conditions
- Advanced Solid Tumor
Interventions
BNT326Drug
Intravenous (IV) infusion
PumitamigDrug
IV infusion
ItraconazoleDrug
Oral administration
ParoxetineDrug
Oral administration
Primary outcomes
What the sponsor says the trial is designed to measure.
- Parts 1 and 2 - All cohorts except Cohort 1F - Occurrence of treatment emergent adverse events (TEAEs), treatment related adverse events (TRAEs), treatment emergent serious adverse events (TESAEs), and treatment related serious adverse events (TRSAEs)Time frame: from first dose of investigational medicinal product (IMP) up to 42 days (Part 1) and 90 days (Part 2) after the last dose of IMP or until a new systemic anti-cancer therapy is started, whichever occurs first (up to 26 months Part 1 or 27 months Part 2)
- Parts 1 and 2 - All cohorts except Cohort 1F - Occurrence of dose interruption, reduction, and treatment discontinuations due to TEAEsTime frame: from first dose of IMP up to 42 days (Part 1) and 90 days (Part 2) after the last dose of IMP or until a new systemic anti-cancer therapy is started, whichever occurs first (up to 26 months Part 1 or 27 months Part 2)
- Parts 1 and 2 - All cohorts except Cohort 1F - Confirmed overall response rate (ORR)Time frame: from the time of initiation of the first dose of IMP up to approximately 38 months (Part 1) and approximately 48 months (Part 2)
- Part 2 - Occurrence of dose limiting toxicities (DLTs)Time frame: from the time of initiation of the first dose of IMP up to 21 days
- Part 1 - Cohort 1F (DDI) only - PK assessment: Maximum concentration (Cmax) derived from serum concentrations of BNT326 ADC and unconjugated payloadTime frame: from the time of initiation of the first dose of IMP up to safety follow-up visit, approximately 42 days post last IMP dose
- Part 1 - Cohort 1F (DDI) only - PK assessment: Area under the curve (AUC) over the last 17-day dosing interval derived from serum concentrations of BNT326 ADC and unconjugated payloadTime frame: from the time of initiation of the first dose of IMP up to safety follow-up visit, approximately 42 days post last IMP dose
Locations
79 sites in 9 countries. Site status is shown where the registry gives one.
Mayo Clinic Arizona
Phoenix, Arizona · Not yet recruiting
University of California San Francisco
San Francisco, California · Not yet recruiting
Hartford Healthcare
Hartford, Connecticut · Recruiting
Yale University
New Haven, Connecticut · Recruiting
Florida Cancer Specialists
Sarasota, Florida · Recruiting
Moffitt Cancer Center
Tampa, Florida · Recruiting
Emory University
Atlanta, Georgia · Not yet recruiting
Dana Farber Cancer Institute
Boston, Massachusetts · Not yet recruiting
Massachusetts General Hospital
Boston, Massachusetts · Recruiting
Brigitte Harris Cancer Pavilion BHCP
Detroit, Michigan · Recruiting
START Midwest, LLC
Grand Rapids, Michigan · Recruiting
Memorial Sloan Kettering Hospital
New York, New York · Recruiting
Duke Cancer Institute
Durham, North Carolina · Not yet recruiting
Cleveland Clinic Taussig Cancer Center
Cleveland, Ohio · Recruiting
University of Pittsburgh Medical Center
Pittsburgh, Pennsylvania · Recruiting
The University of Texas MD Anderson Cancer Center
Houston, Texas · Recruiting
South Texas Accelerated Research Therapeutics (START), LLC
San Antonio, Texas · Recruiting
START Mountain Region
West Valley City, Utah · Recruiting
The Board of Regents of the University of Wisconsin
Madison, Wisconsin · Recruiting
Blacktown Hospital
Blacktown, New South Wales, Australia · Recruiting
St Vincent's Hospital Sydney
Darlinghurst, New South Wales, Australia · Recruiting
Melanoma Institute Australia
Wollstonecraft, New South Wales, Australia · Recruiting
Tasman Oncology Research Ltd
Southport, Queensland, Australia · Recruiting
Cancer Research SA
Adelaide, South Australia, Australia · Recruiting
Peninsula and South Eastern Haematology & Oncology Group
Frankston, Victoria, Australia · Recruiting
Austin Health
Heidelberg, Victoria, Australia · Recruiting
The Alfred Hospital
Melbourne, Victoria, Australia · Recruiting
One Clinical Research Pty Ltd
Nedlands, Western Australia, Australia · Recruiting
Institut Jules Bordet
Anderlecht, Belgium · Recruiting
Universitair Ziekenhuis Gent
Ghent, Belgium · Recruiting
Centre hospitalier universitaire de Liège
Liège, Belgium · Recruiting
Ziekenhuis Aan de Stroom ZAS vzw
Wilrijk, Belgium · Recruiting
Affiliated Hospital of Hebei University
Baoding, China · Not yet recruiting
Chongqing University Cancer Hospital
Chongqing, China · Recruiting
Sir Run Run Shaw Hospital, Zhejiang University, School of Medicine
Hangzhou, China · Recruiting
The Second Affiliated Hospital of Zhejiang University School of Medicine
Hangzhou, China · Recruiting
Guangxi Medical University Affiliated Tumor Hospital
Nanning, China · Not yet recruiting
Tianjin Medical University Cancer Institute & Hospital
Tianjin, China · Recruiting
Hubei Cancer Hospital
Wuhan, China · Recruiting
Charité - Campus Charité Mitte
Berlin, Germany · Recruiting
Showing 40 of 79 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.